Finanzen von DiaMedica Therapeutics Inc (DMAC)DMACDiaMedica Therapeutics Inc

Evaluating the bottom line, DiaMedica Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -114.62%, provide a clear picture of how effectively DMAC converts its operational activities into shareholder value.

In the context of the broader market, DMAC competes directly with industry leaders such as AGMB and PROK. With a market capitalization of $467.54M, it holds a leading position in the sector. When comparing efficiency, DMAC's gross margin of N/A stands against AGMB's N/A and PROK's 100.00%. Such benchmarking helps identify whether DiaMedica Therapeutics Inc is trading at a premium or discount relative to its financial performance.

DiaMedica has reported a consistent net loss over the past quarters, with Q2 2026 showing a loss of $10.1 million. The company has a current ratio of 6.72, indicating good short-term liquidity, but its return on equity (ROE) is significantly negative at -114.62% for Q2 2026, reflecting operational challenges.